Tag: CORE Diagnostics
Oncocyte ties up with CORE Diagnostics to market its cancer testing...
In the United States, DetermaRx™ has rapidly gained traction, expanding to 18 sites in the first three months since commercial launch. The company is now is expanding commercial availability of DetermaRx™ to India, the Middle East and Africa..................
COVID-19 testing starts at CORE Diagnostics Gurgaon lab
To ensure zero contamination of the samples, CORE Diagnostics has setup a separate facility within its high-end Gurgaon lab to perform the confirmatory polymerase chain reaction-based (PCR) COVID-19 test with all strains that are approved by the Government of India.....................
“Diagnostics sector in India is poised for a sharp growth”
In an exclusive interaction with the BioVoice, Zoya Brar, Founder and Managing Director of CORE Diagnostics shared details about the company's journey so far, its vision, market dynamics and much more. Read on..........................
Young Delhi strides against cancer as thousands join ‘Walk for Life’
The walk was organized to draw public attention to the growing and menacing presence of cancer and show support for cancer patients besides raise funds for free of charge home care services to people with cancer in Delhi/NCR and Amritsar...………..
Illumina’s executive chairman talks about precision medicine at CORE Diagnostics meet
Mr Jay Flatley who serves as the Executive Chairman of the Board of Directors, Illumina emphasized on the need for large-scale population study with an Indian cohort as the much needed next step in understanding disease patterns that are specific to people of Indian origin...……...
CORE Diagnostics launches nephroCORE to target kidney disease
CORE’s new addition of nephrology related diagnostic tests comprises of advanced nephro-pathology services, molecular testing for rare and inherited (genetic) kidney diseases, screening for pre and post-transplant infectious diseases, monitoring drug levels, and Transplant Immunology..............
“We are excited about the DNA Bill as a game changer”
Mentioned Dr Rajnish Bharti, General Manager, Promega Biotech in an exclusive face to face interaction with the BioVoice where he also talked about current activities and future outlook...……......
“Being realistic about our capabilities, we always believe in partnerships”
Mentioned Ms Zoya Brar, Founder and Managing Director, Core Diagnostics in an exclusive interaction with the BioVoice, where she talked about latest initaitives and future outlook...........
Promega Biotech India & CORE Diagnostics enter into technology collaboration
The collaboration agreement focuses on the implementation of the Promega Microsatellite Instability (MSI) technology for Immuno-Oncology. The patent-protected MSI technology is considered the gold standard molecular assay for detecting...……...
Significance of ALK gene rearrangement in ‘Non-Small Cell Lung Cancer’ cases...
As per a study by the CORE Diagnostics, the ALK gene mutations is a significant biomarker among Indian patients for targeted therapies in lung cancer and also a boost for Targeted Lung Cancer treatment by directing efforts towards more prevalent genetic biomarkers..........